Hal Allergy
Netherlands - LeidenBiotechnology
Focus: Hal Allergy is a Netherlands-based biotechnology company founded in 2020 specializing in sublingual immunotherapy and allergen-based treatments for seasonal and perennial allergic rhinitis, house dust mite allergy, and food allergies. The company operates as a public-stage biotech with a focused pipeline in the allergy treatment space.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Hal Allergy
AI assessmentNot HiringNo open roles listed right now. Follow Hal Allergy to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
PURETHAL Birch
Stable
Peak
Phase 4 marketed product representing established commercial presence in European allergen immunotherapy market.
PURETHAL Grasses
Help build intelligence for Hal Allergy
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.